The ADC Field Is Flourishing, with new technologies evolving like a raging torrent, propelling biomedicine into a sprint mode, this is the best of times. As early as the beginning of the 20th century, Paul Ehrlich first proposed the concept of the “magic bullet”, but the first ADC drug Mylotarg® (gemtuzumab ozogamicin) was not approved … Read more
The tumor distribution of ADCs depends on many factors, includingthe dose itself, systemic clearance rate, antigen expression level, endocytosis rate, and the tumor’s surface area to volume ratio (S/V). Poor tissue permeability remains a major challenge for antibody treatments of solid tumors, and appropriately increasing the dosage can improve the drug’s tissue distribution and enhance … Read more
ADC Drug Payload Series (Part 2): Microtubule Protein Inhibitor Auristatin Introduction In the previous article, we detailed one of the most widely used microtubule protein inhibitors in ADC drugs: Maytansinoids (see original text). Today, we will continue to explore another class of microtubule protein inhibitors that occupies a significant portion of ADCs—Auristatin. These molecules also … Read more
ADC Field Blooms, new technologies evolve like a rolling tide, propelling biomedicine into high-speed mode. This is the best of times. As early as the early 20th century, Paul Ehrlich first proposed the concept of “magic bullets”; however, the first ADC drug, Mylotarg® (gemtuzumab ozogamicin), was not approved until nearly a century later. Every cloud … Read more